News
APLT
6.84
-0.15%
-0.01
Applied Therapeutics Says FDA Has Extended Review Period For NDA For Govorestat (AT-007) For Treatment Of Classic Galactosemia By Three Months; PDUFA Target Action Date November 28, 2024
FDA requires additional time to review supplemental analyses of previously submitted data. Applied Therapeutics says it remains confident in Galactosemia's potential for approval. The company has extended the PDUFA action date for the drug. The FDA has approved a Major Amendment to the NDA.
Benzinga · 8h ago
Applied Therapeutics Price Target Announced at $12.00/Share by RBC Capital
Dow Jones · 2d ago
Applied Therapeutics Initiated at Outperform by RBC Capital
Dow Jones · 2d ago
RBC Capital Initiates Coverage On Applied Therapeutics with Outperform Rating, Announces Price Target of $12
Benzinga · 2d ago
Weekly Report: what happened at APLT last week (0318-0322)?
Weekly Report · 3d ago
Applied Therapeutics: Registration statement under Securities Act of 1933
Press release · 6d ago
Applied Therapeutics Files Prospectus For Disposition From Time To Time By Selling Stockholders Of Up To 14.3M Shares Of Common Stock
Benzinga · 6d ago
Weekly Report: what happened at APLT last week (0311-0315)?
Weekly Report · 03/18 11:17
Applied Therapeutics Price Target Raised to $13.00/Share From $12.00 by UBS
Dow Jones · 03/15 12:56
Applied Therapeutics Is Maintained at Buy by UBS
Dow Jones · 03/15 12:56
UBS Maintains Buy on Applied Therapeutics, Raises Price Target to $13
Benzinga · 03/15 12:46
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
NASDAQ · 03/13 13:23
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/13 06:20
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. Stocks were lower on Monday, with the Dow Jones index falling more than 150 points. Shares of EQT Corporation fell sharply after the company announced a merger agreement to acquire Equitrans Midstream. Ventyx Biosciences, Inc. Shares tumbled 18.5% to $8.09.
Benzinga · 03/11 14:37
Applied Therapeutics Reveals Strategy and Positive Trial Update
TipRanks · 03/11 12:32
Weekly Report: what happened at APLT last week (0304-0308)?
Weekly Report · 03/11 11:13
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)
Companies in the Healthcare sector have received a lot of coverage today. Applied Therapeutics, Xeris Pharmaceuticals and Arcturus Therapeutic have been recommended by analysts. Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on AppliedTherapeutics. The company has an analyst consensus of Strong Buy for the stock.
TipRanks · 03/11 04:40
Applied Therapeutics’ New Accounting & Financial Operations Risk – A Cause for Worry?
TipRanks · 03/08 06:02
Applied Therapeutics: Annual report
Press release · 03/06 18:05
Applied Therapeutics Price Target Raised to $12.00/Share From $4.00 by UBS
Dow Jones · 03/06 17:49
More
Webull provides a variety of real-time APLT stock news. You can receive the latest news about Applied Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.